NCT02804178View on ClinicalTrials.gov

A Study of ATR-101 for the Treatment of Congenital Adrenal Hyperplasia

PHASE2CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

May 18, 2016

Primary Completion Date

August 17, 2017

Study Completion Date

August 17, 2017

Conditions
Congenital Adrenal Hyperplasia
Interventions
DRUG

ATR-101

125-1000 mg twice per week

Trial Locations (6)

10021

The Children's Hospital of Philadelphia, Philadelphia

20892

National Institutes of Health Clinical Center, Bethesda

21287

Johns Hopkins University, Baltimore

48109

University of Michigan, Ann Arbor

55905

Mayo Clinic - Rochester, Rochester

74135

The University of Oklahoma - Tulsa Schusterman Center, Tulsa

Sponsors
All Listed Sponsors
lead

Millendo Therapeutics, Inc.

INDUSTRY